Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cambridge Heart

This article was originally published in The Gray Sheet

Executive Summary

Microvolt level T-wave alternans measured with the firm's CH2000 test system "was the only statistically significant predictor of sudden death" among seven different clinical measures evaluated in a study of 107 congestive heart failure (CHF) patients followed for 18 months, the firm reports. Published in the Aug. 19 issue of The Lancet, the study included patients with no prior history of sustained ventricular arrhythmias. The study shows the technology to be "the most effective non-invasive test to identify [CHF] patients at risk for developing life-threatening abnormal heart rhythms," the firm maintains. The CH2000 system was cleared by FDA in 1996, and labeling was expanded in April 1999 to include the prediction of risk for severe cardiac arrest
Advertisement
Advertisement
UsernamePublicRestriction

Register

MT013779

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel